Ultragenyx Pharmaceutical (NASDAQ:RARE) has been evaluated by four analysts in the past three months, with all four maintaining a 'Somewhat Bullish' stance. The average 12-month price target for RARE is now $100.0, down 11.11% from the previous average, with a high estimate of $130.00 and a low of $72.00. Analysts from Cantor Fitzgerald, Wells Fargo, Morgan Stanley, and Piper Sandler have provided ratings and adjusted price targets, reflecting their views on the company's market position and financial performance. Ultragenyx Pharmaceutical is a biopharmaceutical company focusing on rare and ultra-rare diseases, with products like Crysvita, Dojolvi, and Mepsevii. Financially, the company has a high market capitalization and a positive revenue growth rate of 8.1%, but faces challenges with a net margin of -162.82%, ROE of -198.64%, ROA of -12.52%, and a high debt-to-equity ratio of 1.47.